Introduction
Mammalian viruses have evolved multiple strategies in order to evade the immune system of their host and thus guarantee their own spreading and survival. Besides inducing expression of host cellular proteins (Zhu et al., 1998; Birkenbach et al., 1993) , viruses have adopted host genes and structurally optimized their products for particular pharmacological phenotypes to bene®t the virus. Thus, certain members of the large DNA virus families, i.e. the Herpesviridae and the Poxviridae have incorporated chemokines and/or chemokine receptors from their hosts into their own viral genome (Wells and Dairaghi et al., 1998; Lalani and McFadden, 1999; Ahuja and Murphy, 1999) . In addition, several poxviruses (Lalani and McFadden, 1999) and the MHV68 (murine gherpesvirus 68) (Parry et al., 2000; van Berkel et al., 2000) produce soluble very broad spectred chemokine binding proteins for sequestration of the host's chemokine pool (so-called chemokine scavengers). This review focuses on the pharmacology and biology of virally encoded 7TM (seven trans-membrane segments), G-protein coupled receptors mainly from members of the Herpesviridae family. Although it has long been known that certain viruses are associated with the development of tumours, only recently a causative link was made between a virally encoded chemokine receptor, i.e. the ORF74 receptor from HHV8 (human herpesvirus 8) and tumorigenesis (Kaposi's sarcoma) (Yang et al., 2000) . Other virally encoded chemokine receptors, i.e. U12 from HHV6 and US28 from human CMV (cytomegalovirus), have been implicated to play a role in disease development of certain lymphomas, multiple sclerosis and atherosclerosis; however any causative link to these diseases has not ®nally been proven for these viral receptors.
In the case of HHV6, there was some enthusiasm that this virus could be one of the aetiological agents in lymphomas and leukaemias when it was isolated from patients with lymphoproliferative disorders in 1986 (Salahuddin et al., 1986) . Early in vitro studies revealed that HHV6 DNA fragments ± one of which included the viral chemokine receptor U12 ± could transform cells and induce tumours in nude mice. However, these studies had some major caveats (reviewed in Campadelli-Fiume et al., 1999) , so the present view is to look at the virus as an innocent bystander (Luppi and Torelli, 1996) . Interestingly, cases of lymphomas and acute lymphoblastic leukaemia have been reported, where the viral genome has been integrated into host chromosomes, but the biological signi®cance of these observations still remains elusive (Luppi et al., 1993; Daibata et al., 1998 Daibata et al., , 1999 . In addition, HHV6 is neurotropic and has been linked to multiple sclerosis, since it has been shown: (i) to cause exanthema subitum and is associated with febrile convulsions (Hall et al., 1994) ; (ii) to establish a latent infection in the CNS (Challoner et al., 1995) ; (iii) to be located in the nuclei of oligodendrocytes in multiple sclerosis (Challoner et al., 1995) ; and (iv) to cause a strong IgM response against HHV6 antigens in patients with relapsing intermittent sclerosis (Soldan et al., 1997) . However, other serological studies have been unable to link HHV6 to multiple sclerosis (Enbom et al., 1999; Mirandola et al., 1999) . Nevertheless, if HHV6 does play a role in this disease, it could very well be, that the chemokine receptors U12 and U51 or the HHV6B encoded chemokine U83 are involved in plague formation, e.g., by stimulating cell proliferation or attracting cells from the immune system.
Mammalian chemokines and chemokine receptors
Chemokines (chemotactic cytokines) are a family of small molecular weight proteins (8 ± 12 kD) that bind to and signal through 7TM G-protein coupled receptors. Their main function is to attract and activate distinct leukocyte subsets, for example to in¯ammatory foci and to speci®c tissues or micro-environments, e.g., within lymph nodes. The chemokine superfamily consists of more than 40 members, most of which can be classi®ed into one of two groups distinguished by the presence (CXC) or absence (CC) of a single amino acid between the ®rst two of the four conserved cysteines. To date, 28 CC chemokines, 16 CXC chemokines, a C as well as a CX3C chemokine are known (according to the recently introduced new chemokine nomenclature by the International Union of Pharmacology Nomenclature for Chemokines and Chemokine Receptors the CC and the CXC chemokines are designated CCL# and CXCL#, respectively. In analogy, CX3C and C chemokines are designated CX3CL# and XCL#, respectively. All chemokine names in this review will be followed by the new nomenclature, for example IP-10/ CXCL10) ± and this number is still increasing Rollins, 1998; Horuk, 1994) . In fractalkine/ CX3CL1 and CXCL16 the chemokine domain is anchored to a membrane spanning domain by a large mucin-like stalk, which comprises 40 ± 75% of the whole molecule (Fong et al., 2000; Matloubian et al., 2000) . CC chemokines are usually involved in in¯ammatory reactions with attraction of various cell types, e.g. monocytes, macrophages, eosinophils and basophils. CXC chemokines are further subdivided into two families, the ELR+ and ELR7 chemokines, based on the presence or absence of a Glu-Leu-Arg sequence located just before the ®rst cysteine. ELR+ chemokines preferentially attract neutrophils, whereas ELR7 chemokines preferentially attract lymphocytes (Rollins, 1998) . Another important biologic function of the CXC chemokines is an angiomodulatory activity, especially in relation to in¯ammatory processes. The ELR+ CXC chemokines, e.g. GROa/CXCL1 usually are angiogenic, whereas the ELR7 CXC chemokines, e.g. IP-10/ CXCL10 and SDF-1a/CXCL12, usually are angiostatic (Strieter et al., 1995; Moore et al., 1998) . This angiomodulatory eect combined with the direct eect of chemokines on leucocyte in®ltration of tumour tissues and on tumour cell migration and proliferation manifest, that the chemokine system also has a central role in tumour growth and metastasis .
To date, 11 dierent receptors for the CC chemokines, CCR1-11, and six dierent receptors for the CXC chemokines, CXCR1-6, have been identi®ed together with XCR1 that binds lymphotactin/XCL1 and CX3CR1 that binds fractalkine/CX3CL1. In addition to the CC and CXC receptors, two nonsignalling 7TM chemokine receptors (often referred to as chemokine binding proteins due to the lack of signal transduction events upon ligand binding), D6 and Duy, have been characterized. Both D6 and Duy bind a broad spectrum of chemokines, and Duy also functions as an entry factor for the malaria-causing protozoan Plasmodium vivax. For a recent review of chemokine receptors see Murphy et al. (2000) . The ligand binding properties of CC and CXC chemokine receptors range from high selectivity to high promiscuity. However, in general there is no cross-talk between the CC versus CXC families. Characteristic for the chemokine system as such, is a very large degree of redundancy. Chemokine receptors are mainly found on leucocytes, but some chemokine receptors are also expressed on non-haematopoietic cells including neurons, epithelial and endothelial cells, thus pointing to important functional properties of chemokines beyond the immune system.
Virally encoded chemokines and chemokine receptors
More than 10 dierent virally encoded chemokines and approximately the same number of chemokine receptors have as yet been identi®ed based on sequence similarities to human counterparts (Wells and .
Human a-herpesviruses (herpes simplex etc.) do not in general encode chemokines, chemokine receptors or chemokine binding proteins; however, Marek's disease virus (a lymphotropic chicken a-herpesvirus) encodes an IL-8/CXCL8 like CXC chemokine, that until now remains uncharacterized (Lee et al., 2000) .
b-herpesviruses are slow growing viruses with a restricted host range and usually cause infected cells to enlarge (cytomegali). They tend to establish latency in haematopoietic progenitor cells and persistently infect epithelial and glandular cells. Human, rat, and murine CMV as well as HHV6 and -7 (human herpes virus 6 and -7) are members of this family. They all encode one or more 7TM receptors with homology to human chemokine receptors and some encode chemokine homologues.
g-herpesviruses exhibit a narrow host range. Of these, EBV (Epstein ± Barr virus) does not encode any components of the chemokine system; however, upon cell-entry EBV induces increased expression of several host chemokine receptors. HHV8 (or KSHV, Kaposi's sarcoma associated herpesvirus) as well as the animal g-herpesviruses, herpesvirus Saimiri (a squirrel herpesvirus), MHV68 (murine g-herpesvirus 68), and EHV2 (equine herpesvirus-2) all encode chemokines and/or chemokine receptors and many members cause fulminate lymphomas and other neoplasias in the haemopoietic system of their hosts. Animal models of herpesvirus Saimiri and MHV68, including genetically modi®ed virus (Clambey et al., 2000) , have contributed to a greater understanding of the immunology and virological aspects of g-herpesvirus pathogenesis, since these viruses are able to establish both acute and persistent infection in laboratory mice (Simas and Efstathiou, 1998; Jung et al., 1999) . These studies have shown that during the acute phase, virus replication is detected in multiple organs, whereas latency is mainly restricted to B-lymphocytes and macrophages.
Virally encoded chemokines cover the whole spectrum of biologic activities exerted by a given ligand, thus being either agonists, antagonists, inverse agonists or a combination of those on dierent receptors. Agonists are for instance UL146 from human CMV (Penfold et al., 1999) , U83 from HHV6 (Zou et al., 1999) and vMIP-I and -III from HHV8 Endres et al., 1999; Stine et al., 2000) . Antagonists are for example vMIP-II from HHV8 (Kledal et al., 1997) and MC148 from Molluscum contagiosum virus (Damon et al., 1998; LuÈ ttichau et al., 2000) and in addition, inverse agonistic properties have been ascribed to vMIP-II from HHV8 (Rosenkilde et al., 1999 ). An in vivo study of vMIP-II has uncovered anti-in¯ammatory properties for this chemokine in a rat model of experimental glomerulonephritis (Chen et al., 1998) . In this model vMIP-II potently inhibited chemokine induced chemotaxis of activated leukocytes isolated from nephritic glomeruli and signi®cantly reduced leukocyte in®ltration to the glomeruli. Thus virally encoded proteins, here exempli®ed by vMIP-II, may serve as useful templates for the development of anti-in¯ammatory compounds.
Viral homologues of 7TM chemokine receptors have been identi®ed in human, murine and rat CMV as well as in HHV6 and -7 together with the g-herpesviruses HHV8, herpesvirus Saimiri, MHV68, and EHV2 and two poxviruses (for details see Table 1 ). Only half of these viral chemokine receptors have been characterized in respect of signal transduction and chemokine binding properties. In addition, their role during the viral life cycle and in viral pathogenesis is poorly understood. However, several models to elucidate their function in vivo are under development, for instance animals infected with genetically modi®ed viruses and transgenic animals expressing virally encoded chemokine receptors (Beisser et al., 1998 (Beisser et al., , 1999 Yang et al., 2000) . Figure 1 presents dendrograms based on amino acid identity of all currently known human and human virus-encoded chemokine receptors. In the right dendrogram, the length of the branches re¯ects the actual identity, whereas the left dendogram has a restricted and uniform length of each branch irrespective of the identity. These dendrograms indicate, that human and virally encoded chemokine receptors are rather far from each other with low sequence identities, and that they form two main clusters ± one on each side of the dendrograms. It is also interesting to note that the proposed`close' functional similarity between certain virally encoded receptors and selected human receptors, for instance between ORF74 from HHV8 and human CXCR2, and between US28 from CMV and human CCR1 is not really evident in the sequencebased dendrograms. The main cluster of virally encoded 7TM receptors is divided into four families:
. The U12/UL33 family from HHV6, HHV7, and CMV (rat, murine and human CMV) . The U51/UL78 family from HHV6, HHV7, and CMV (rat, murine and human CMV) . The US27/US28 family from human CMV . The ORF74 family from g-herpesviruses (only HHV8 is included in the dendrograms; however, herpesvirus Saimiri, EHV2, and MHV68 also encode a 7TM receptor located in open reading frame 74, ORF74).
In addition, both HHV6 and HHV7 have been shown to upregulate CCR7 expression in T-cells just like EBV does in B-cells upon cell entry (Hasegawa et al., 1994) .
The U12/UL33 family
The genomes of HHV6A, -6B and -7 contain homologues for two 7TM receptors, U12 and U51 (Gompels et al., 1995; Nicholas, 1996) . Of these, the U12 receptors are found in the chemokine receptor dendrogram in a branch together with UL33 from CMV ( Figure 1 ). Very little is known about the U12 receptors; however, certain CC chemokines, including RANTES/CCL5 have been reported to elicit calcium release via U12 from HHV6 (Isegawa et al., 1998) . Gene knock-out experiments in both murine and rat CMV have shown that M33 and R33, respectively ± the homologues of UL33 from human CMV ± are important for the general virulence, since they both are essential for targeting and/or replication of the rodent CMV in salivary glands. No CMV could be detected in salivary glands of mice and rats inoculated with murine and rat CMV, respectively, where the UL33 homologous genes had been disrupted (Davis-Poynter et al., 1997; Beisser et al., 1998) .
The U51/UL78 family
The U51 receptors are found in the chemokine receptor dendrogram in a branch together with UL78 from CMV ( Figure 1 ). U51 from HHV6 is known to be expressed on the surface of infected T-cells , and has been found to bind RANTES/CCL5 with nanomolar anity as well as to downregulate the transcription of this chemokine (Milne et al., 2000) . Very few pharmacological data are available concerning the UL78's, encoded by rat (R78), murine (M78) and human (UL78) CMV. However, they are clearly 7TM receptors, and they have been shown to in¯uence the virulence. Thus, one study on a R78-de®cient rat CMV-strain revealed a 10 ± 100-fold lower replication eciency than wild-type virus and a lower mortality rate in infected rats. Thus, R78 is suggested to play an important role in both CMV replication in vitro and in the pathogenesis of viral infection in vivo (Beisser et al., 1999) .
The US27/US28 family
Of the four human CMV encoded 7TM receptors, US28 is the most extensively characterized. It is a broad spectred chemokine receptor that binds a large number of endogenous CC chemokines with very similar nanomolar anity (Kuhn et al., 1995) in addition to the HHV8 encoded vMIP-II (Kledal et al., 1998) . However, interestingly US28 has been optimized to speci®cally recognize and bind the membrane associated chemokine fractalkine/CX3CL1, which has been suggested to play a role in the cell to cell transfer of virus (Kledal et al., 1998) . In accordance with the promiscuous CC chemokine binding pro®le, US28 has also been suggested to act as a cellularly expressed chemokine scavenger ± which acts by endocytosis and subsequent elimination of the chemoattractant chemokines from the surroundings of infected cells (Bodaghi et al., 1998; Vieira et al., 1998; Billstrom et al., 1999) . Like many human chemokine receptors ± US28 can function as a cofactor for HIV cell-entry when expressed concomitantly with CD4 (Plesko et al., 1997) and moreover US28 can mediate cell-fusion together with other envelope proteins from, for example, vesicular stomatitis virus (Plesko et al., 1998) . This may be mediated through US28-fractalkine/CX3CL1 binding (Kledal et al., 1998) . US28 signals through the Gq-phospholipase C (PLC) pathway in a highly constitutive manner (Casarosa et al., 2000) . However, the ligand dependent increase in intracellular calcium levels by various CC chemokines (Gao and Murphy, 1994) and the activation of the ERK1/2 kinase pathway (Billstrom et al., 1998) are linked to Gi and G16, respectively. In addition, US28 activates the transcription factor NFkB in a G-protein dependent way (Shibutani et al., 1997; Carlquist et al., 1999; Casarosa et al., 2000) .
US27 is located immediately upstream of US28 in the genome of human CMV (Bodaghi et al., 1998) . Despite this close vicinity and around 40% sequence homology to US28, US27 does not bind any of the chemokines known to interact with US28. However, the cellular distribution of US27 resembles the one of UL33 and US28 since it is found mainly intracellularly in perinuclear surroundings, endocytic vesicles and only to a little extent on the cell-surface (Vieira et al., 1998) .
CMV has been suggested to be one of the aetiological factors behind atherosclerosis (Melnick et al., 1983; Nieto, 1999) and has been found to be a risk factor for re-stenosis after coronary atherectomy (Zhou et al., 1996) . However, it was not until late 1999 that a molecular mechanism underlying this pathogenic property of CMV was substantiated experimentally. In vitro infections with a US28 de®cient CMV strain showed, that US28 was responsible for the CMV induced smooth muscle cell migration (Streblow et al., 1999) and thus possibly causing the accumulation of smooth muscle cells in the re-stenosis lesions.
The ORF74 family encoded by g-herpesviruses All 7TM receptors encoded by g-herpesviruses ± except for E1 and E6 (see Table 1 ) encoded by EHV2 ± are localized in the so-called open reading frame 74 of the viral genome. Consequently, ORF74 is a general term used for these receptors. Alternatively, many dierent names have been used as presented in Table 1 . The ORF74's are functionally most related to human CXCR2; however, as depicted on the dendrograms in Figure 1 Dendrogram of human and virally encoded chemokine receptors. The phylogenetic trees were constructed using Clustal W 1.5 alignments of the full amino acid sequence followed by an analysis by the Distance program (GCG, Genetics Computer Group, the Wisconsin Package). TreeView, http://taxonomy.zoology.gla.ac.uk/rod/rod.html was used for the graphic presentation. Chemokine receptors encoded by human herpesviruses are included in the dendrograms together with human chemokine receptors. The receptors are coloured as follows: CC chemokine receptors (blue letters), CXC chemokine receptors (green letters), EBI-2, XCR1, CX3CR1 and the two non-signalling chemokine binding proteins D6 and Duy (black letters) and the human herpesvirusencoded receptors (red letters). The ®rst identi®ed ORF74 was ECRF3 encoded by herpesvirus Saimiri (Ahuja and Murphy, 1993 ). This herpesvirus is T-cell lymphotropic and establishes asymptomatic infections in its natural host, the squirrel monkey, but causes fatal lymphoproliferative diseases in other new world primates. Like CXCR2, ECRF3 binds several ELR+ chemokines such as GROa/ CXCL1 and IL-8/CXCL8 with nanomolar anities, and a rapid release in intracellular Ca 2+ is elicited upon binding of e.g. GROa/CXCL1 to ECRF3 (Ahuja and Murphy, 1993) . In contrast to ECRF3 and ORF74 from HHV8, ligand binding and signalling properties of ORF74's from MHV68 and EHV2 have not yet been described. However, sequence similarities to ECRF3 and ORF74 from HHV8 predict CXCR2-like properties.
ORF74 from HHV8
When the genome of HHV8 was resolved in 1996 it was found to hold a 7TM-like gene, ORF74 Neipel et al., 1997; Cesarman et al., 1996) . When the ORF74 was expressed it became clear that the receptor displayed an unusually high degree of constitutive signalling activity (Arvanitakis et al., 1997; Rosenkilde et al., 1999) . Like US28, but unlike endogenous chemokine receptors, ORF74 signals through the Gq pathway, leading to activation of phospholipase-C (PLC) and a high constitutive turnover of phosphatidyl-inositol (Arvanitakis et al., 1997; Rosenkilde et al., 1999) . Furthermore, ORF74 activates the JNK/SAPK and p38 mitogen activated phosphokinase (MAP) pathways (Bais et al., 1998) mediated by Related Adhesion Focal Tyrosine Kinase (RAFTK) (Munshi et al., 1999) . The concerted action of these signalling pathways induces the production and secretion of VEGF (vascular endothelial growth factor) via the transcription factor, hypoxia inducible factor (HIF)-1a (Sodhi et al., 2000) and results in cellular transformation which can develop into highly vascularized tumours when transplanted into nude or SCID mice (Bais et al., 1998) .
ORF74 binds almost all known CXC chemokines with high anity (Arvanitakis et al., 1997; Rosenkilde et al., 1999; . ELR+ CXC chemokines act either as agonists (Gershengorn et al., 1998; Rosenkilde et al., 1999) , e.g. GROpeptides/CXCL1 and CXCL3, green symbols in Figure  2 or as neutral ligands, e.g. IL-8/CXCL8 and NAP-2/ CXCL7, grey symbols in Figure 2 (Rosenkilde et al., 1999) , whereas ELR-CXC chemokines act as inverse agonists, e.g. IP-10/CXCL10 and SDF-1a/CXCL12, red symbols in Figure 2 (Geras-Raaka et al., 1998a,b; Rosenkilde et al., 1999) . Thus, ORF74 is stimulated by endogenous chemokines that exhibit angiogenic properties, while it is inhibited by endogenous chemokines that exhibit angiostatic or angiomodulatory properties.
HHV8 has been suggested to be causatively involved in three disorders of the haematopoietic system, Kaposi's sarcoma, body cavity associated lymphoma (or primary eusion lymphoma, PEL), and multicentric Castleman's disease (Chang et al., 1994; Cesarman et al., 1995; Soulier et al., 1995; Dupin et al., 1999; Parravicini et al., 2000) . HHV8 infection typically precedes these disorders (Gao et al., 1996) and HHV8 genes ± including ORF74 ± are detectable in the respective lesions (Staskus et al., 1997; Dupin et al., 1999; Cesarman et al., 1996; Guo et al., 1997) . ORF74 from HHV8 is a lytic gene expressed in HHV8 infected lymphocytes during the early phases of the virus' lytic replication cycle (Kirshner et al., 1999) . As presented above (Figure 2 ), ORF74 exploits endogenous ligands which are normally involved in the regulation of angiogenesis and neovascularization in the host organism (Strieter et al., 1995; Moore et al., 1998; Rosenkilde et al., 1999) . Accordingly, the high constitutive activity of the receptor and its in¯uence on VEGF secretion regulated by endogenous chemokines (Bais et al., 1998) are important events in the angiomodulatory activity of ORF74. In addition, HHV8 infection of primary human endothelial cell cultures in vitro results in sustained upregulation of the expression of VEGF receptor 2 (VEGFR-2) (Flore et al., 1998) . Hence, in various ways, ORF74 and more generally HHV8 infection are involved in angiogenesis, both through interaction with angiomodulatory chemokines and through induction of VEGF and its receptor, VEGFR-2.
A variety of both in vitro and in vivo studies describe transforming properties for ORF74. ORF74 stimulates growth and transformation of transfected cells (Arvanitakis et al., 1997; Bais et al., 1998; Rosenkilde et al., 1999) . NIH3T3 cells transiently expressing ORF74 develop foci within a few weeks and subsequent injection of these transformed cells into SCID mice results in large vascularized tumours Agonistic chemokines are depicted as green symbols, GROa/ CXCL1 as circles and GROg/CXCL3 as triangles. Inverse agonistic chemokines are depicted as red symbols, IP-10/CXCL10 as squares and SDF-1a/CXCL12 as triangles. Chemokines with no in¯uence on basal activity ± neutral ligands ± are depicted as grey symbols, IL8/CXCL8 as diamonds and NAP-2/CXCL7 as squares. Redrawn from (Rosenkilde et al., 1999) (Bais et al., 1998) . Gq coupled 7TM receptors are in general able to transform cells. When overexpressed by transfection in for example NIH3T3 cells, Gqcoupled receptors can function as proto-oncogenes as orginally described for the Serotonin 5HT1c receptor (Julius et al., 1989) . This phenomenon has been used in the development of functional assays for measuring activity of Gq coupled receptors as well as many other receptors (BraÈ uner-Osborne and Brann, 1996) . However, in the case of ORF74, the transforming activity in NIH3T3 cells is much higher than observed with e.g. the 5TH1 or the muscarinic receptors (Rosenkilde et al., 1999) .
The ®rst in vivo evidence for a causative link between ORF74 and tumorigenesis, i.e. Kaposi's sarcoma, was elegantly presented by Sergio Lira and co-workers (Yang et al., 2000) . ORF74 was placed under the control of the human CD2 promoter, which speci®cally targets the gene to expression in certain haematopoietic cells. This single gene from HHV8 expressed transgenically in mice resulted in angioproliferative lesions localized in the skin, main extremities, ears, tail and in the gut. Subsequently, these lesions lead to erythematous plaques and further progressed to nodules and eventually highly vascularized tumours (Figure 3) . The macroscopic appearance, the localization as well as the histology of these lesions closely resembled Kaposi's sarcoma lesions in humans. Although only a small subset (8 ± 10%) of cells within the lesions expressed ORF74, the receptor was found on NKand T-cells that in®ltrated the angioproliferative lesions. The low expression pro®le of ORF74 is in accordance with the expression pattern observed for other lytic HHV8 encoded genes in Kaposi's sarcoma lesions in humans (Staskus et al., 1997; Orenstein et al., 1997; Kirshner et al., 1999; Sun et al., 1999) . In contrast, latently expressed HHV8 genes can be detected in almost all Kaposi's sarcoma tumour cells (Dupin et al., 1999) , emphasizing the putative role of HHV8 in the pathogenesis of this disease. In general, 7TM receptors are excellent drug targets and due to the oncogenic potential, ORF74 could represent a new interesting drug-target (Schwartz, 1994; LuÈ ttichau and Schwartz, 2000) .
Kaposi's sarcoma lesions are not characterized by the mere uncontrolled proliferation of a single cell type, but by a very high degree of neovascularization. Although the ligand independent signalling activity of ORF74 originally was expected to be involved in the generation of Kaposi's sarcoma lesions (Arvanitakis et al., 1997) , it is interesting to note that the virus apparently has carefully selected angiogenic chemokines as agonists and angiostatic chemokines as antagonists, as presented in Figure 2 (Rosenkilde et al., 1999) . Thus, it could be expected that this modulation of activity by endogenous chemokines also contribute to the transforming properties of ORF74. Through protein engineering of ORF74 a series of pharmacological phenotypes with modulated constitutive activity and/or ligand binding pro®le have been generated, which can be exploited to address this basic question. For example, truncations of the N-terminus of ORF74 eliminates binding of all chemokines, without in¯uencing its high basal activity as presented in Figure 4 , upper left box (Ho et al., 1999; . Another interesting phenotype in which the agonist ± but not inverse agonist ± action is eliminated, is obtained by mutating the Arg residues at the extracellular ends of TM-V (Figure 4 , upper right box). Most interestingly, introduction of an Asp residue for Leu 91 in the middle of TM-II, [L91D]-ORF74 eliminates the high constitutive activity while preserving the ability of the receptor to be stimulated by GROa/CXCL1 ( Figure  4 , lower left box). In vivo expression of these speci®cally altered receptor phenotypes under control of the CD2 promoter in transgenic mice has uncovered the fact, that the oncogenic potential of ORF74 from HHV8 is not only dependent on the high constitutive activity, but importantly is also dependent on the modulation by endogenous angiogenic chemokines (Holst et al., unpublished observation) . Virally encoded and induced 7TM receptors ± tools for virus survival?
The characterization of the virally encoded or induced chemokine receptors point towards functional properties of these receptors which can be exploited in several aspects of the viral life cycle. Thus, the receptors are probably used by the virus for either cellular activation or control of cellular machinery, immune evasion, tissue targeting, and possibly for cell entry. The redundancy in the chemokine system might be one reason for the many dierent ways for the virally encoded chemokine receptors of attacking the cellular machinery. These dierent ways are summarized in Figure 5 for selected human herpesvirus-encoded chemokine receptors and some will be described more detailed in the following section.
Optimization of binding to certain endogenous chemokines
ORF74 from HHV8 and US28 from CMV are similar in their broad spectred recognition of either CXC or CC chemokines, respectively. However, among the many ligands that US28 interacts with, fractalkine/CX3CL1 binding is in fact highly speci®c, as the CC chemokines cannot compete for fractalkine/CX3CL1 binding (Kledal et al., 1998) . The interaction between US28 (expressed on the virally infected cell and virus envelope) and fractalkine (expressed on a target cell) has been suggested to present an initial interaction between virus and target cell, and to enhance and maybe even mediate the cell-fusion process (Kledal et al., 1998) (Figure 5 ). This model was recently supported by a study using a cell¯ow assay ± where out of a variety of CC chemokines tested ± fractalkine/CX3CL1 was the most potent chemokine in capturing US28 expressing cells (Haskell et al., 2000) .
ORF74 from HHV8 has been optimized to recognize angiogenic CXC chemokines as agonists and angiostatic chemokines as inverse agonists (green and red symbols in Figure 2 , respectively) with binding of these`active' chemokines very dierent from binding of the neutral ligands (grey symbols in Figure 2 ). Thus radiolabelled agonist and inverse agonist cannot be displaced by the neutral ligands i.e. in¯ammatory chemokines (Rosenkilde et al., 1999; . This phenomenon also applies to ECRF3 (or ORF74) from herpesvirus Saimiri, which in turn also is selective for GROa/CXCL1 as opposed to the in¯ammatory CXC chemokine IL-8/CXCL8 (Ahuja and Murphy, 1993) .
Altering signalling pathways from fine-tuned ligand dependent receptor regulation to high-ligand independent-constitutive activity Chemokine receptors normally signal mainly through the G i pathway ; however, certain virally encoded receptors have changed signal transduction pathways to become highly constitutive active G q -signalling with activation of the phospholipase C pathway and subsequent increase in phosphatidyl-inositol turnover (Arvanitakis et al., 1997; Rosenkilde et al., 1999; Casarosa et al., 2000) ( Figure  5 ). Nevertheless, both ORF74 and US28 utilize various chemokines to modulate their constitutive activity (Figure 2 ). PI-turnover via US28 can be partially suppressed by fractalkine/CX3CL1 (Casarosa et al., 2000) . This ± together with the above proposed fractal-kine-based cell-cell fusion mechanism ± might facilitate the virus' cell entry by a fractalkine/CX3CL1 mediated`silencing' of US28 in order to provide an optimal environment for spreading and budding of the virus.
Interference with mitogenic proteins (MAP-kinases) and transcription factors (NF-kB) US28 from human CMV and ORF74 from HHV8 both activate the major MAP-kinase pathways, i.e., ERK1/2, JNK/STAT and p38 (Bosho, 1998; Sodhi et al., 2000) and both have recently been shown to activate the transcription of NF-kB (Casarosa et al., 2000) ; however, a detailed knowledge of the signalling pathways leading to NF-kB activation still remains elusive.
Cellular-distribution to compartments that secures incorporation in the viral envelope and spreading of the virus UL33 from human CMV has in fact been shown to occur in the virus envelope (Margulies et al., 1996) . In contrast to most human chemokine receptors, only a small amount of the virally encoded US28, US27 and UL33 is expressed on the cell surface. The majority of the protein accumulates mainly in early and late endosomal compartments (Fraile-Ramos et al., in preparation) . Interestingly, during viral infections, these intracellular compartments are the places where viral envelope formation takes place and most of these receptors are found to be expressed in the actual envelope of the virion late in the infectious process.
Thus, the virus might have optimized those receptors which are targeted to the viral envelope to function as immediate early genes. For example, the constitutively active receptor US28 could function in a ligand independent fashion right after the fusion between either the viral envelope or between the infected cell and the`target cell'. In this way they may change the Figure 5 Model of the cellular pathways exploited by US28 and ORF74. A schematic model with indication of signalling pathways for the two virally encoded receptors. Upper half represents biologic activities of US28 from human CMV (blue serpentine receptors), for instance the proposed chemokine scavenger function, where CC chemokines (illustrated by light blue circles) binds to US28 and gets internalized with the receptor and consequently removed from the surface. The signalling through Ca 2+ release, PIturnover, MAP-kinases and NFk-B are also indicated. Finally, the selective interaction between US28 and fractalkine/CX3CL1 (illustrated by dark blue circles on stalks) with proposed function in the fusion-process between virus and cell is indicated in the membrane of a neighbouring cell. The activities of ORF74 from HHV8 (green serpentine receptors) are indicated on the lower half of the ®gure. The main actions of this receptor are activation of PI-turnover in a ligand independent, but putatively ligand modulated, high constitutive activity, activation of MAP-kinases and NFk-B. These cellular pathways result in VEGF release and consequently angiogenesis, and to cellular transformation and development of highly vascularized tumours. The activating (angiogenic) ± CXC chemokines are indicated as green circles, whereas the inhibitory (angiostatic) ± CXC chemokines are indicated as red circles functional state of the cell through the various signalling cascades and alter gene expression.
Induction of chemokine receptors by herpesvirus
EBV has been strongly associated with many tumours (see Table 1 ). Several oncogenes have been identi®ed in the EBV genome, but surprisingly and as mentioned previously, EBV does not encode any chemokine or chemokine receptor. However, in infected B-cells, EBV induces the expression of the chemokine receptor CCR7, which was originally known as EBI-1 or Epstein ± Barr induced-I as well as EBI-II, which is still an orphan 7TM receptor (Birkenbach et al., 1993) . CCR7 is required for ecient adaptive immune responses by functioning as a homing switch that is turned on during activation of resting T-cells and maturing dendritic cells ± thereby accumulating lymphocytes and dendritic cells in the secondary lymphoid system (FoÈ rster et al., 1999; Yoshida et al., 1997) .
HHV6 and HHV7 have been shown to upregulate CCR7 expression in T-cells just like EBV does in Bcells upon cell entry (Hasegawa et al., 1994) . This induction of CCR7 by EBV in the infected B-cell and by HHV6 and HHV7 in infected T-cells can be envisioned to serve as a way for the virus to`tell' the infected cells to migrate to lymph nodes etc.
Conclusively, the virally encoded chemokine receptors change the cellular machinery in several ways, and functional properties of many dierent virally encoded receptors and ligands still need to be uncovered and described. In general, the viruses have managed to identify important targets (here chemokine elements) and ensure their own survival by exploiting or subverting these targets. We can use these mechanisms not only in the treatment of various infectious diseases, but more importantly, also in the treatment of in¯ammatory and proliferative diseases. The virus often point to interesting new targets, like the CCR8 receptor, which speci®cally is targeted by the virally encoded chemokine MC148 from poxvirus (LuÈ ttichau et al., 2000) . Thus, anything from AIDS to in¯amma-tory diseases like rheumatoid arthritis, chronic in¯am-matory bowel diseases up to various cancers should be reachable and targeted from a drug development point of view ± based on lessons learned from viruses.
